Warning: count(): Parameter must be an array or an object that implements Countable in /home/customer/www/drugtrialsformoney.com/public_html/wp-content/plugins/redux-framework/redux-core/inc/classes/class-redux-output.php on line 373
FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL - Drug Trials For Money - Paid Clinical Trials

FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL

FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL
Conditions:   NHL;   Non Hodgkin Lymphoma;   Diffuse Large B Cell Lymphoma;   High-grade B-cell Lymphoma
Interventions:   Drug: FT596;   Drug: Rituximab
Sponsor:   Masonic Cancer Center, University of Minnesota
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

October 1, 2020 / by / in
Comments